Neuroleptic malignant syndrome: A neuroimmunologic hypothesis

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 18, 2010, Pages

  Anglin, Rebecca E ^a   Rosebush, Patricia I ^a   Mazurek, Michael F ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ANTIPYRETIC AGENT; AUTOANTIBODY; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; C REACTIVE PROTEIN; CREATINE KINASE; DANTROLENE; DOPAMINE 2 RECEPTOR; FIBRINOGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 1; INTERLEUKIN 6; IRON; NEUROLEPTIC AGENT; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; AGITATION; ANTIBODY PRODUCTION; ARTICLE; COOLING; CYTOKINE RELEASE; DEHYDRATION; ELECTROCONVULSIVE THERAPY; ENVIRONMENTAL TEMPERATURE; HEAT STRESS; HUMAN; INFECTIOUS MONONUCLEOSIS; IRON BLOOD LEVEL; LEUKOCYTE ACTIVATION; LEUKOCYTOSIS; MACROPHAGE; MENTAL STRESS; MONOCYTE; MUSCLE INJURY; NEUROIMMUNOLOGY; NEUROLEPTIC MALIGNANT SYNDROME; REHYDRATION; REYE SYNDROME;

EID: 78650073321     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.091442     Document Type: Article

References (30)

1. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989;146:717-25.
2. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870-6.
3. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association; 2000. p. 798.
4. Keck PE, Pope HG, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome: A case-control study. Arch Gen Psychiatry 1989;46:914-8.
5. Troller JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999;33:650-9.
6. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome: are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 1991;159:709-12.
7. Henderson VW, Wooten GF. Neuroleptic malignant syndrome: A pathogenetic role for dopamine receptor blockade? Neurology 1981;31:132-7.
8. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999;156:169-80.
9. Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet 1991;328:149-51.
10. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
11. Burger D, Dayer J. Cytokines, acute-phase proteins, and hormones. Ann N Y Acad Sci 2002;966:464-73.
12. Bouchama A, Knochel JP. Heat stroke. N Engl J Med 2002;346:1978-88.
13. Rosebush PI, Anglin RE, Richards C, et al. Neurolptic malignant syndrome and the acute phase response. J Clin Psychopharmacol 2008;28:459-61.
14. Lee S. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998;44:499-507. (Pubitemid 28451939)
15. Ben-Shachar D, Finberg JPM, Youdim MBH. Effect of iron chelators on dopamine D2 receptors. J Neurochem 1985;45:999-1005.
16. Tanaka S, Matsunaga H, Kimura M, et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol 2003;141:155-64.
17. Kelton JG. The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest 2005;(Suppl 2)127:9S-20S.
18. Pullen H, Wright N, Murdoch JM. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet 1967;2:1176-8.
19. Levy M. The combined effect of viruses and drugs in drug-induced diseases. Med Hypotheses 1984;14:293-6.
20. Chong TW, Castle DJ. Layer upon layer: thermoregulation in schizophrenia. Schizophr Res 2004;69:149-57.
21. Taylor C, Rogers G, Goodman C, et al. Hematologic, iron-related and acute-phase protein responses to sustained strenuous exercise. J Appl Physiol 1987;62:464-9.
22. Griffiths JD, Camphell IJ, Woodruff IW, et al. Acute changes in iron metabolism following myocardial infarction. Am J Clin Pathol 1985;84:649-54.
23. Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia. Clin Neuropharmacol 2002;25:183-93.
24. Araki M, Takagi A, Higuchi I, et al. Neuroleptic malignant syndrome: caffeine contracture of single muscle fibers and muscle pathology. Neurology 1988;38:297-301.
25. Lopez JR, Sanchez V, Lopez MJ. Sarcoplasmic ionic calcium concentration in neuroleptic malignant syndrome. Cell Calcium 1989;10:223-33.
26. Deak T, Meriwether JL, Fleshner M, et al. Evidence that brief stress may induce the acute phase response in rats. Am J Physiol 1997;273(6 pt 2):R1998-2004.
27. White DA. Catatonia and the neuroleptic malignant syndrome - a single entity? Br J Psychiatry 1992;161:558-60.
28. Rosebush PI, Hildebrand A, Furlong BG, et al. Catatonic syndrome on a general psychiatric ward: frequency, clinical presentation and response to lorazepam. J Clin Psychiatry 1990;51:357-62. (Pubitemid 20370455)
29. Nguyen KT, Deak T, Owens SM, et al. Exposure to acute stress induces brain interleukin-1b protein in the rat brain. J Neurosci 1998;18:2239-47.
30. Allen RP, Earley CJ. The role of iron in restless legs syndrome. Mov Disord 2007;22: S440-8.